Loading...
•
Mar 31, 2022
Jaguar Health Q1 2022 Earnings Report
Reported consolidated first quarter 2022 financial results and provided company updates.
Key Takeaways
Jaguar Health reported a 112% increase in Mytesi net revenue compared to Q1 2021, reaching $2.6 million, and Canalevia-CA1 is now commercially available.
Mytesi net revenue increased approximately 24% over the fourth quarter of 2021.
Mytesi net revenue was approximately $2.6 million in the first quarter of 2022.
Mytesi total prescription volume increased 14.6% in the first quarter of 2022 over the fourth quarter of 2021.
Canalevia-CA1, for chemotherapy-induced diarrhea in dogs, is now commercially available.
Forward Guidance
Jaguar Health anticipates continued development initiatives for crofelemer, efforts to forge license and business development relationships, the ongoing Canalevia-CA1 launch, potential expansion of Canalevia conditional approval to exercise-induced diarrhea (EID) in dogs; and continued growth in sales of Mytesi.
Positive Outlook
- Continued development initiatives for crofelemer
- Efforts to forge license and business development relationships
- Ongoing Canalevia-CA1 launch
- Potential expansion of Canalevia conditional approval to exercise-induced diarrhea (EID) in dogs
- Continued growth in sales of Mytesi
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...